{"denoms":[{"counts":[{"groupId":"BG000","value":"85"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"129"}],"units":"Participants"}],"groups":[{"description":"Ripretinib (150 mg) once daily in 28-day cycles until disease progression by Independent Radiologic Review (IRR) in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior therapies (therapies must include treatment with imatinib, sunitinib, and regorafenib). Ripretinib vs. Placebo 2:1 ratio","id":"BG000","title":"Ripretinib"},{"description":"Placebo once daily in 28-day cycles until disease progression by Independent Radiologic Review (IRR) in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior therapies (therapies must include treatment with imatinib, sunitinib, and regorafenib). Ripretinib vs. Placebo 2:1 ratio","id":"BG001","title":"Placebo"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"57"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"79"}],"title":"18 - 64 Years"},{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"32"}],"title":"65 - 74 Years"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"18"}],"title":"75 Years or Older"}],"title":"Age Category (years)"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"56"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"73"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"76"},{"groupId":"BG001","value":"38"},{"groupId":"BG002","value":"114"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"14"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"9"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"10"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"97"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"12"}],"title":"Not Reported"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Other"}],"title":"Race"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"60"}],"title":"US"},{"measurements":[{"groupId":"BG000","value":"45"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"69"}],"title":"Non-US"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"81"}],"title":"3"},{"measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"48"}],"title":"≥ 4"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Number of Prior Systemic Anticancer Treatments","unitOfMeasure":"Participants"}],"populationDescription":"The baseline analysis population was the intent-to-treat (ITT) population, defined as those who signed the ICF and were randomized"}